Literature DB >> 19053265

Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl.

Jeffrey P Froehlich1, James E Mahaney, Gizem Keceli, Christopher M Pavlos, Russell Goldstein, Abiona J Redwood, Carlota Sumbilla, Dong I Lee, Carlo G Tocchetti, David A Kass, Nazareno Paolocci, John P Toscano.   

Abstract

Nitroxyl (HNO) donated by Angeli's salt activates uptake of Ca(2+) by the cardiac SR Ca(2+) pump (SERCA2a). To determine whether HNO achieves this by a direct interaction with SERCA2a or its regulatory protein, phospholamban (PLN), we measured its effects on SERCA2a activation (as reflected in dephosphorylation) using insect cell microsomes expressing SERCA2a with or without PLN (wild-type and Cys --> Ala mutant). The results show that activation of SERCA2a dephosphorylation by HNO is PLN-dependent and that PLN thiols are targets for HNO. We conclude that HNO produces a disulfide bond that alters the conformation of PLN, relieving inhibition of the Ca(2+) pump.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053265     DOI: 10.1021/bi801925p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  44 in total

Review 1.  The emergence of nitroxyl (HNO) as a pharmacological agent.

Authors:  Christopher H Switzer; Wilmarie Flores-Santana; Daniele Mancardi; Sonia Donzelli; Debashree Basudhar; Lisa A Ridnour; Katrina M Miranda; Jon M Fukuto; Nazareno Paolocci; David A Wink
Journal:  Biochim Biophys Acta       Date:  2009-05-06

2.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

3.  Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674.

Authors:  Steve Lancel; Jingmei Zhang; Alicia Evangelista; Mario P Trucillo; Xiaoyong Tong; Deborah A Siwik; Richard A Cohen; Wilson S Colucci
Journal:  Circ Res       Date:  2009-03-05       Impact factor: 17.367

4.  Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A.

Authors:  Kim N Ha; Larry R Masterson; Zhanjia Hou; Raffaello Verardi; Naomi Walsh; Gianluigi Veglia; Seth L Robia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 5.  The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems.

Authors:  Wilmarie Flores-Santana; Debra J Salmon; Sonia Donzelli; Christopher H Switzer; Debashree Basudhar; Lisa Ridnour; Robert Cheng; Sharon A Glynn; Nazareno Paolocci; Jon M Fukuto; Katrina M Miranda; David A Wink
Journal:  Antioxid Redox Signal       Date:  2011-03-16       Impact factor: 8.401

6.  Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.

Authors:  Guangshuo Zhu; Dieter Groneberg; Gautam Sikka; Daijiro Hori; Mark J Ranek; Taishi Nakamura; Eiki Takimoto; Nazareno Paolocci; Dan E Berkowitz; Andreas Friebe; David A Kass
Journal:  Hypertension       Date:  2014-12-01       Impact factor: 10.190

Review 7.  A recent history of nitroxyl chemistry, pharmacology and therapeutic potential.

Authors:  Jon M Fukuto
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

Review 8.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 9.  Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.

Authors:  Barbara K Kemp-Harper; John D Horowitz; Rebecca H Ritchie
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 10.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.